Author name: Chris Green

Case Study: AggreGuard improves viral kinetics in measles process

Leave a Comment / Case Study / By

Enhancement Potential for a Classical Batch-Mode Upstream Measles Process*: Impact of AggreGuard™ AggreGuard™, a CellRev product, was independently evaluated in a commercially relevant measles vaccine process without altering standard operating protocol, showing: ↓ cell-to-cell adhesion and ↑ cell culture homogeneity. ↓ glucose/glutamine consumption and ↓ lactate/ammonia production. ↑ viral infection kinetics and ↓ time to …

Case Study: AggreGuard improves viral kinetics in measles process Read More »

Kuraray and CellRev Partner to support optimised cell culture systems in Regenerative Medicine

Leave a Comment / Featured, News / By

(Newcastle Upon Tyne, 11th June 2025) The Kuraray Life Innovation Business Promotion Department, a division of Kuraray Co., Ltd. (TYO: 3406), a global leader in specialty chemicals, and Cellularevolution Ltd. (CellRev), an innovative developer of bioprocessing media additives, have entered into a strategic partnership aimed at enhancing cell culture solutions within the mesenchymal stem cells …

Kuraray and CellRev Partner to support optimised cell culture systems in Regenerative Medicine Read More »

Why upstream bioprocess inefficiencies are the Vaccine industry’s silent saboteur

Leave a Comment / Blog, Featured / By

In the race to make vaccines faster, cheaper, and more equitably distributed, one challenge has quietly dragged behind the spotlight: upstream bioprocess inefficiencies. These early-stage production bottlenecks are where promising vaccine candidates either scale into commercial success or fizzle into sunk costs. And yet, despite their impact, upstream processes are often treated as rigid frameworks—something …

Why upstream bioprocess inefficiencies are the Vaccine industry’s silent saboteur Read More »

Why tackling cell clumping could be the breakthrough the Vaccine industry needs

Leave a Comment / Blog / By

In the shadow of pandemics, resurging viruses, and global vaccine inequality, the way we manufacture vaccines is more important than ever. Despite massive technological leaps in genetic sequencing, AI-assisted drug discovery, and cold-chain logistics, one fundamental aspect of vaccine production has stubbornly resisted progress: the way we grow the cells that produce them. At CellRev, …

Why tackling cell clumping could be the breakthrough the Vaccine industry needs Read More »

Enzyme-Powered Bioprocessing: A Three-Course Menu for Modern Manufacturing

Leave a Comment / Blog / By

Enzymes are nature’s quiet overachievers, and at CellRev, we’re giving them a seat at the head of the bioprocessing table. This blog explores how our enzymes are transforming cell culture workflows from sticky messes to smooth, scalable systems. Here’s your three-course tasting menu. Starter: The Age-Old Alchemy of Enzymes From cheese to cell therapy, nature’s …

Enzyme-Powered Bioprocessing: A Three-Course Menu for Modern Manufacturing Read More »

App Notes: AggreGuard & Kuraray Scapova AS used to culture human adipose-derived stem cells

Leave a Comment / Application Note / By

Discover how our partner Kuraray Co. Ltd, achieved a 7-fold increase in cell count using a combination of Scapova™ AS PVA microcarriers and AggreGuard™. Designed to increase cell viability and eliminate processing bottlenecks, AggreGuard controls and reduces cell-to-cell adhesion without affecting cell-to-surface attachment. In this study, ADSCs were cultured in serum-free medium on iMatrix-511-coated SCAPOVA™ …

App Notes: AggreGuard & Kuraray Scapova AS used to culture human adipose-derived stem cells Read More »

Case Study: AggreGuard improves productivity, an eGFP model

Leave a Comment / Case Study / By

AggreGuard™ facilitates reduced upstream process optimisation and increases eGFP-production post-transduction Cell-to-cell adhesion is the main driver of cell clumping and microcarrier aggregation in suspension-based agitated bioreactors.  CellRev tested a hypothesis: reducing cell-to-cell adhesion with AggreGuard™ in a representative upstream bioprocess can improve the viral titre while maintaining cell culture homogeneity without cell line engineering or …

Case Study: AggreGuard improves productivity, an eGFP model Read More »

Poster: Advanced Therapies London 2025

Leave a Comment / Poster / By

Controlling cell-to-cell adhesion to facilitate process optimisation and intensification As presented by our Head of Technology at Advanced Therapies London in 2025, this poster provides an overview of the transformative benefits of AggreGuard on microcarrier-based cultures. Download Now

Case Study: Continuase empowering continuous processing

Leave a Comment / Case Study / By

Continuase™: Empowering continuous cell manufacturing on multiple technology platforms for different scaling strategies In this case study CellRev demonstrates how Continuase™, a proprietary media additive, is capable of controlling cell-to-surface attachment. Continuase™ was used to develop a first of its kind continuous biomanufacturing process on different bioreactors to showcase clear techno-economic advantages for the emerging …

Case Study: Continuase empowering continuous processing Read More »

Cell rev Logo-white

Technology

About Us

Join our mailing list

Vector dot
The Biosphere, Draymans Way, Newcastle upon Tyne, NE4 5BX
Terms and ConditionsCookie policyTerms of Purchase